Hyloris Pharmaceuticals SA 2025 SR
The report outlines Hyloris' commitment to sustainability, focusing on its strategic alignment with the Corporate Sustainability Reporting Directive (CSRD) and European Sustainability Reporting Standards (ESRS). Key environmental initiatives include conducting environmental risk assessments and operating from a BREEAM-certified headquarters. On the social front, the company highlights its diverse workforce, balanced gender ratio, and focus on addressing unmet medical needs, such as the opioid crisis and cardiovascular diseases. In terms of governance, Hyloris emphasizes its Code of Conduct, ethical clinical trials, and efforts to reinforce its internal control framework.
Company: Hyloris Pharmaceuticals SA
Sector: Health Care
Country: Belgium
Year: 2025
Type: SR
Pages: 15
Hyloris Pharmaceuticals SA
ESG Report
The report outlines Hyloris' commitment to sustainability, focusing on its strategic alignment with the Corporate Sustainability Reporting Directive (CSRD) and European Sustainability Reporting Standards (ESRS). Key environmental initiatives include conducting environmental risk assessments and operating from a BREEAM-certified headquarters. On the social front, the company highlights its diverse workforce, balanced gender ratio, and focus on addressing unmet medical needs, such as the opioid crisis and cardiovascular diseases. In terms of governance, Hyloris emphasizes its Code of Conduct, ethical clinical trials, and efforts to reinforce its internal control framework.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Workplace Fatalities
Employees